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Abstract 
Purpose: Haloperidol and clonidine are commonly used to treat agitation in delirious intensive care unit (ICU) 
patients, but it is unclear whether these agents may shorten the duration of delirium. The objective of this study was 
to determine whether haloperidol, clonidine, or their combined administration to delirious ICU patients results in 
delirium resolution.
Methods: This was a cohort study on a mixed ICU, excluding patients with a primary neurological disorder. The main 
outcome was the probability of delirium resolution, using propensity score matching and Markov multinomial logistic 
regression models for daily transitions. Secondary outcomes were delirium duration, number of delirium days, ventila‑
tion days, length of stay in the ICU and hospital, and ICU mortality.
Results: A total of 3614 patients were included (1165 delirious [32%]; 2449 non‑delirious [68%]). Delirium occurred 
on 4708 (18.9%) of 24,906 days. The probability of delirium resolution was lower in delirious patients who received 
haloperidol (OR 0.47, 95% CI 0.39–0.57), clonidine (OR 0.78, 95% CI 0.63–0.97), or both (OR 0.45, 95% CI 0.36–0.56) 
compared to untreated delirious patients. Delirious patients who received haloperidol, clonidine, or both had gener‑
ally longer delirium duration, more delirium and ventilation days, and spent more time in the ICU and in hospital than 
untreated delirious patients. These agents had no effect on ICU mortality.
Conclusion: Haloperidol and clonidine use in delirious ICU patients may be associated with reduced probability of 
delirium resolution. This finding, however, merits further investigation given inherent limitations of this observational 
analysis.
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Introduction
Delirium is a clinical manifestation of acute encephalopa-
thy and a frequent complication in critically ill patients 
[1–4]. Patients who experience delirium during intensive 
care unit (ICU) admission are more likely to have a longer 
stay in the ICU and hospital, and are more likely to incur 
higher healthcare costs than patients without delirium [5, 
6]. Delirium is further associated with an increased risk 
of long-term cognitive impairment [7, 8]. However, man-
aging delirium remains a challenge for ICU physicians as 
an established treatment is lacking [9].
Pharmacological management of delirium is cur-
rently based on inferences of presumed pathophysiol-
ogy. A widely used drug for treating delirium in a critical 
care setting is haloperidol, a dopamine D2 antagonist 
[10]. However, little evidence is available to support its 
use in treatment of all patients with delirium [9]. Two 
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randomized trials have studied the efficacy of haloperidol 
versus placebo as treatment of ICU delirium. One was a 
pilot trial conducted in mechanically ventilated patients 
admitted to a medical or surgical ICU [11], and the other 
was a therapeutic trial in patients with acute respiratory 
failure or shock [12]. These trials have shown that halo-
peridol does not deliver a difference of more than two 
delirium- and coma-free days when compared to placebo. 
However, a smaller difference could still be clinically 
relevant.
In addition to an excess of dopaminergic activity, it has 
been hypothesized that delirium results from an excess of 
norepinephrine activity [13]. The release of norepineph-
rine is inhibited by dexmedetomidine, an alpha-2 agonist, 
which has recently gained popularity for treating agitated 
delirium in mechanically ventilated patients [14, 15]. 
However, it is only available as intravenous preparation 
and, due to its costs, may not be the preferred agent for 
all critically ill patients [16]. Clonidine is another alpha-2 
agonist that is less expensive and may therefore be an 
alternative to dexmedetomidine. Clonidine is available in 
both intravenous and enteral formulations, and is regu-
larly administered to treat agitation in both mechanically 
ventilated and non-ventilated ICU patients [17]. A ran-
domized controlled pilot trial in cardiothoracic surgery 
patients showed promising results regarding delirium 
severity [18]. Yet, to our knowledge no studies have been 
conducted on the efficacy of clonidine for treatment of 
delirium in a mixed ICU [19].
We hypothesized that treatment with haloperidol and/
or clonidine would increase the likelihood of resolving 
delirium. The aim of this cohort study was therefore to 
determine whether administration of haloperidol, cloni-
dine, or their combined use was associated with resolu-
tion of delirium in critically ill patients.
Methods
Study design and participants
This study was based on a prospectively enrolled cohort 
of patients admitted to the mixed ICU of the Univer-
sity Medical Center Utrecht the Netherlands between 
August 2011–June 2013 and June 2015–March 2019 [20, 
21]. In between these two periods no data have been col-
lected, due to lack of available research staff. Details on 
the patients in the first cohort have been published [22]. 
For the current analysis, exclusion criteria were ICU 
admission < 24  h, readmissions, transfers from another 
ICU, or admission with a primary acute neurological or 
neurosurgical disorder confounding the delirium diag-
nosis [23], or another condition that could hamper the 
assessment of delirium, such as mental retardation, 
anoxic brain injury after cardiopulmonary resuscitation, 
or inability to speak Dutch or English. ICU physicians 
adhered to a sedation protocol aiming for light sedation 
(target Richmond Agitation and Sedation Scale [RASS] 
score − 2 to 0), without using dexmedetomidine. Because 
of the non-interventional nature of this investigation, 
the ethics committee of the University Medical Center 
Utrecht waived the need for informed consent (proto-
col #19-768/c). This cohort study was reported using the 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement [24].
Data collection and definitions
All data have been collected prospectively. Age, sex, 
ICU admission type, Acute Physiology and Chronic 
Health Evaluation (APACHE) IV [25], and ICU and hos-
pital length of stay were stored in the electronic patient 
data management system. On a daily level (one day was 
defined as a 24-h epoch from 10AM to 09.59AM), the fol-
lowing characteristics were collected: modified Sequen-
tial Organ Failure Assessment (SOFA) score (without 
the central nervous system component) [26], presence of 
metabolic acidosis (defined as base excess < − 3 in arterial 
blood gas analysis), mechanical ventilation status, mor-
tality, and administration of antipsychotics (haloperidol, 
quetiapine, olanzapine, clozapine, risperidone), sedatives 
(benzodiazepines, propofol, clonidine) and opioids.
Patients were prospectively classified per 24-h epoch 
as awake without delirium, delirious, unarousable, dis-
charged or dead. The daily mental status was classified 
according to a delirium recognition algorithm based on 
three items [22]: (1) the RASS and Confusion Assess-
ment Method-Intensive Care Unit (CAM-ICU) scores, 
assessed by bedside nurses, (2) evaluation of medical 
charts for signs of delirium i.e. altered consciousness 
and > 1 symptoms of delirium, and (3) additional delirium 
assessments by trained researchers. If in a 24-h period at 
least one of these items was positive for delirium, patients 
were classified as delirious. In this current cohort study, 
the initiation of haloperidol or quetiapine was not used to 
classify patients as delirious. Sedation was assessed every 
three hours with the RASS [27]. On a daily level, an una-
rousable state was defined as all RASS scores on that day 
being < − 3 or − 3 combined with sedative use—imped-
ing delirium assessment [28]. Patients were classified as 
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awake without delirium if they had at least one RASS 
score > − 4, or > − 3 if in combination with sedative use, 
in a 24-h period, with all delirium assessments in that 
period being negative. With regards to delirium dur-
ing ICU stay, patients were classified as delirious if they 
had at least one day with a positive delirium assessment 
according to the before mentioned algorithm.
Outcomes
The primary outcome was transitioning from delirium on 
any given day (day X) to an awake state without delirium 
on the following day (day X + 1). Secondary outcomes 
were delirium duration (in days), number of delirium and 
ventilation days, length of stay in the ICU and hospital 
(in days), and ICU mortality. Delirium duration was the 
number of consecutive days that a patient was classified 
as delirious or unarousable during the first delirium epi-
sode in the ICU. As delirium may fluctuate over time and 
as patients may transition between delirium and una-
rousable states during a delirium episode, we defined a 
delirium episode as ended if the patient was awake with-
out delirium for at least two consecutive days.
Statistical analysis
Continuous data were summarized with medians and 
interquartile ranges (IQR) or means with standard devia-
tions, depending on distribution. Categorical variables 
were shown as proportions with percentages. To describe 
differences between patients who were ever delirious 
and patients who were never delirious, continuous vari-
ables were compared using Mann–Whitney U tests or 
independent t tests, and categorical outcomes with Chi 
square tests. For differences in baseline medication expo-
sures, we used logistic and linear regression analyses.
For the primary analysis the delirious observation 
days were used. We studied whether the administration 
of haloperidol, clonidine, or both haloperidol and clo-
nidine on any given delirium day (day X) was associated 
with a transition to an awake state without delirium on 
the following day (day X + 1), compared to the probabil-
ity of either remaining delirious or transitioning to una-
rousable state on day X + 1, with mortality and discharge 
on day X + 1 being competing events (Online Resource 
1). The combination of delirium and unarousable state 
on the following day was chosen as a comparator, as we 
specifically aimed to assess delirium resolution as transi-
tion to an awake state without delirium and to minimize 
confounding of the treatment to the delirium assessment 
due to sedative side-effects of haloperidol [29] and cloni-
dine [30]. For the primary analysis we used a first-order 
Markov multinomial logistic regression model. Model 
1 involved administration of haloperidol only (yes/no), 
clonidine only (yes/no), or both haloperidol and cloni-
dine (yes/no) on day X. Additionally, to examine dose-
dependency, we modeled two main predictors (Model 
2): (1) dosage of intravenously administered haloperi-
dol in milligrams on day X, with a conversion of 0.6 per 
milligram enterally administered haloperidol based on 
bioavailability, and (2) dosage of intravenously adminis-
tered clonidine in micrograms on day X. To control for 
confounding, we included the following covariates to 
both Markov models: age, APACHE IV score, and admis-
sion type (acute surgery, elective surgery, medicine). 
Additionally, we included the following daily covariates: 
patients’ mental status on day X, modified SOFA score, 
metabolic acidosis (yes/no), use of mechanical ventilation 
(yes/no), and administration of any antipsychotic other 
than haloperidol (yes/no), benzodiazepines or propo-
fol (yes/no), and opioids (yes/no). These covariates were 
associated with delirium development, or were suspected 
to confound the studied association [31].
Additionally, we used propensity score matching for the 
primary analysis to match delirium days without medica-
tion exposure with delirium days on which haloperidol, 
clonidine, or both was administered. The match tolerance 
was set to 0.001. We adjusted for confounding by includ-
ing the same covariates as in the Markov models.
Three sensitivity analyses were performed. First, as 
both haloperidol and clonidine may have mild seda-
tive effects [29, 30], they may influence the CAM-ICU 
assessment. Likewise, agitated delirious patients may 
have received more haloperidol and/or clonidine than 
patients with hypoactive delirium. Hence, our first sen-
sitivity analysis stratified outcomes by delirium motor 
subtypes, comparing “hyperactive delirium days” (all 
RASS scores on that delirium day > 0), “hypoactive delir-
ium days” (all RASS scores on that delirium day ≤ 0) and 
“mixed delirium days” (RASS scores of both > 0 and ≤ 0 
on that delirium day). Second, we assessed whether the 
implementation of the 2013 Pain, Agitation and Delirium 
guideline [32] and general changes in ICU delirium man-
agement over the years affected the resolution of delirium 
by assessing the effect of the inclusion period (2011–2013 
versus 2015–2019). Third, as the clinical effects of halo-
peridol and clonidine may become apparent 24  h after 
administration, we examined whether there was an asso-
ciation of the administration of haloperidol and/or cloni-
dine on delirium day X with transition to an awake state 
without delirium on day X + 2, using the same analysis as 
for X + 1.
Secondary analyses were performed on patient level in 
delirious patients instead of the level of observation-days 
to assess whether the administration of haloperidol, clo-
nidine or both haloperidol and clonidine versus none of 
these agents during ICU stay was associated with the sec-
ondary outcomes. Linear regression models were used to 
analyze delirium duration, number of delirium and ven-
tilation days, and ICU and hospital length of stay. ICU 
mortality was analyzed with a logistic regression model. 
These models were adjusted for age, APACHE IV score, 
admission type, highest modified SOFA score during 
ICU stay, presence of metabolic acidosis during ICU stay 
(yes/no), ventilation during ICU stay (yes/no), delirium 
duration (in days), and administration of any antipsy-
chotic other than haloperidol (yes/no), benzodiazepines 
or propofol (yes/no) and opioids (yes/no) during ICU 
stay. If needed, log transformation of the variables was 
performed.
Analyses were performed in SPSS, version 25, and 
Markov multinomial logistic regression analyses were 
performed in R, version 3.5.1. To evaluate the goodness 
of fit, likelihood ratio tests, F values and R2 values were 
used. Observations were excluded if delirium classifica-
tion was missing. A two-sided p value less than 0.05 was 
considered statistically significant.
Results
Study population and observation days
During the study periods, 12,380 patients were admitted 
to the ICU. After applying inclusion and exclusion crite-
ria, we included 3614 patients (details outlined in Online 
Resource 2). Among these, 1165 (32%) experienced delir-
ium during ICU stay and were used for the analyses. The 
median age was 63 years (IQR 52–72) and 2286 (63.3%) 
were male (Table 1). Patients with delirium were signifi-
cantly older, had a higher APACHE IV score, and were 
more often admitted with a medical or an acute surgical 
diagnosis than patients without delirium.
See Online Resource 3, Table  1 for the characteristics 
of the observations days. Delirium occurred on 4708 
(18.9%) of 24,906 observation days, which were used for 
the primary analysis. Haloperidol and clonidine were 
more frequently administered on delirium days than on 
days in which patients were unarousable or awake with-
out delirium, and more often on mixed/hyperactive delir-
ium days than hypoactive delirium days (Online Resource 
3, Table 2).
No values were missing for the predictors. For the 
covariates, values were missing for ICU admission type 
(0.1%), APACHE IV score (5.3%), modified SOFA score 
(3.9%) and patients’ mental status on day X (14.2%).
Daily transitions and administration of haloperidol 
and clonidine
From the 4708 delirium days, 1101 (23.4%) patients tran-
sitioned to an awake state without delirium the follow-
ing day, while 2712 (57.6%) remained delirious and 269 
(5.7%) transitioned to an unarousable state. Additionally, 
509 (10.8%) were discharged or died, and from 117 (2.5%) 
the mental status on the following day was missing. The 
transition flow including data on the receipt of haloper-
idol and clonidine is shown in Fig.  1. Patients in whom 
delirium resolved the following day were administered 
haloperidol and/or clonidine less frequently and in lower 
dosages than patients who remained delirious or transi-
tioned to an unarousable state.
Table 1 Characteristics of included patients, stratified by delirium status during ICU stay
APACHE IV Acute Physiology and Chronic Health Evaluation IV, ICU Intensive Care Unit, IQR interquartile range, LOS length of stay
a Difference between patients who were ever delirious and those who were never delirious
b Missing data were present for some patients: medical ICU admission type 2 (0.1%); acute surgery ICU admission type 2 (0.1%); elective surgery ICU admission type 2 
(0.1%), APACHE IV score 190 (5.3%); mechanical ventilation, ever 15 (0.4%)
Characteristic All patients (n = 3614) Ever delirious (n = 1165) Never delirious (n = 2449) p  valuea
Age, years (IQR) 63 (52–72) 64 (54–73) 63 (51–71) < 0.001
Male, n (%) 2286 (63.3%) 763 (65.5%) 1523 (62.2%) 0.055
ICU admission type
 Acute surgery, n (%)b 700 (19.4%) 319 (27.4%) 381 (15.6%) < 0.001
 Elective surgery, n (%)b 1688 (46.7%) 359 (30.8%) 1329 (54.3%) < 0.001
 Medicine, n (%)b 1224 (33.9%) 487 (41.8%) 737 (30.1%) < 0.001
APACHE IV score (IQR)b 54 (39–74) 69 (53–87) 47 (35–64) < 0.001
ICU LOS, days (IQR) 2.6 (1.2–5.9) 6.8 (3.7–13.1) 1.8 (1.1–3) < 0.001
Hospital LOS, days (IQR) 13.3 (7.1–25.9) 24.2 (14–42.9) 9.9 (6–218.3) < 0.001
Mechanical ventilation, ever, n (%)b 3374 (93.4%) 1135 (97.7%) 2239 (91.9%) < 0.001
ICU mortality, n (%) 345 (9.5%) 139 (11.9%) 206 (8.4%) 0.001
Table 2 Haloperidol and clonidine use on day X and delirium resolution on the following day
Markov regression model (Model 1). Mortality or discharge on day X + 1 was included as a competing event. The model fitted the data well (χ2(63) = 13,578.841, 
p < 0.001)
CI confidence interval, OR Odds ratio
a Adjusted for age, APACHE IV score, admission type (acute surgery, elective surgery, medical reason), patients’ mental status on day X, modified SOFA score, 
metabolic acidosis, use of ventilation, and administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids
Mental status 
on day X
Exposure on day X Mental status on day X + 1 Adjusted OR (95% CI)a p value
Delirious No haloperidol or clonidine Delirious or unarousable Reference
Delirious Haloperidol only Awake without delirium 0.47 (0.39–0.57) < 0.001
Delirious Clonidine only Awake without delirium 0.78 (0.63–0.97) 0.025
Delirious Both haloperidol and clonidine Awake without delirium 0.45 (0.36–0.56) < 0.001
Fig. 1 Daily transitions of mental status including administration of haloperidol and clonidine on delirium day X with median dosages. CI confi‑
dence interval, IQR interquartile range, Mcg microgram, Mg milligram, OR Odds ratio. a509 (10.8%) patients were deceased or discharged on day 
X + 1 and for 117 (2.5%) patients the mental status on the following day was missing. bSignificant (p < 0.001) difference in frequency of administra‑
tion as compared to delirium or unarousable on day X + 1, tested with logistic regression models, adjusted for age, APACHE IV score, admission 
type (acute surgery, elective surgery, medical reason), patients’ mental status on day X, modified SOFA score, metabolic acidosis, use of ventilation, 
and administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids. Adjusted OR (95%CI) for haloperidol only 
was 0.66 (0.55–0.78) and for both haloperidol and clonidine 0.59 (0.48–0.73). cSignificant (p < 0.05) difference in dose of administered medication 
as compared to delirium or unarousable on day X + 1, tested with linear regression models, adjusted for age, APACHE IV score, admission type 
(acute surgery, elective surgery, medical reason), patients’ mental status on day X, modified SOFA score, metabolic acidosis, use of ventilation, and 
administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids. Adjusted OR (95% CI) for haloperidol only was 
0.96 (0.93–0.98), for clonidine only 0.88 (0.83–0.93), for haloperidol in case of both haloperidol and clonidine administration 0.95 (0.92–0.98) and for 
clonidine in case of both haloperidol and clonidine administration 0.9 (0.85–0.95)
Markov modeling and propensity score matching 
of haloperidol and clonidine administration and delirium 
resolution
As shown in Table 2, the administration of haloperidol on 
a delirium day was associated with significant lower odds 
of delirium resolution on the following day (OR 0.47; 95% 
CI 0.39–0.57), as was administration of clonidine (OR 
0.78; 95%CI 0.63–0.97) and the use of both haloperidol 
and clonidine (OR 0.45; 95% CI 0.36–0.56). Propensity 
score matching yielded similar results as our primary 
analyses (Online Resource 4).
Further, the odds ratio of delirium resolution was 0.84 
(95% CI 0.81–0.88) for every 1  mg administered halo-
peridol, and 0.98 (95% CI 0.97–1) per 100  µg clonidine 
(Model 2, Table 3).
The results of the three sensitivity analyses are reported 
in Online Resource 5. First, due to the low number 
of hyperactive delirium days, we analyzed these days 
together with mixed delirium days. The use of haloperi-
dol or both haloperidol and clonidine on a hyperactive/
mixed or hypoactive delirium day was associated with 
significantly lower odds on delirium resolution, while 
clonidine was not. Second, similar findings were obtained 
for the inclusion periods 2011–2013 and 2015–2019, 
with administration of clonidine only being associated 
with lower odds of delirium resolution for inclusion 
period 2015–2019 only. Last, lower probabilities of delir-
ium resolution on day X + 2 were found for haloperidol 
only and both haloperidol and clonidine, but not for clo-
nidine only.
Secondary outcomes
As shown in Table  4, the administration of haloperidol, 
clonidine, or both haloperidol and clonidine in delirious 
patients was associated with increased delirium dura-
tion, more delirium days, and a longer stay in the ICU. 
These patients also spent more time in the hospital than 
untreated delirious patients, with exception for patients 
who were administered clonidine only. Additionally, the 
number of ventilation days was higher in patients who 
were administered both haloperidol and clonidine. There 
was no difference in ICU mortality.
Discussion
In summary, our study suggests that treatment of ICU 
delirium with haloperidol, clonidine, or both haloperidol 
and clonidine might reduce the probability of delirium 
resolution. These associations were dose-dependent, and 
consistent with almost all secondary outcomes.
Our findings with regards to haloperidol as delirium 
treatment are in line with previous observational studies, 
in which higher delirium rates were found with haloperi-
dol use [33]. In non-intubated patients, each additional 
milligram of haloperidol was associated with 5% higher 
odds of delirium on the following day [34]. Another retro-
spective study found that treatment of delirious patients 
with antipsychotics (quetiapine, olanzapine, risperidone 
or haloperidol) was associated with a longer delirium 
duration and ICU stay [35]. However, our observations 
that haloperidol might be associated with reduced proba-
bility of delirium resolution and increased delirium dura-
tion are partly in contrast with two recent randomized 
controlled trials [12, 36]. These trials found that halop-
eridol is not associated with prevention or resolution of 
delirium, and the number of delirium days. These differ-
ences may be explained by our time-dependent Markov 
analysis focusing on daily transitions, instead of the num-
ber of delirium days in a certain (limited) study period. 
We found that the use of haloperidol and clonidine on 
delirium days was associated with reduced probabilities 
of delirium resolution within 48  h after administration. 
It might be that these agents have negative short-term 
effects on delirium resolution, but that these effects will 
disappear after 48  h or more. Second, our results may 
differ due to differences in study populations and dosage 
regimens. We had a high percentage of surgical patients 
(66.1%) as compared to 28% in the study by Girard et al. 
[12]. Finally, the optimal dosage of haloperidol and/
or clonidine as delirium treatment remains unknown. 
Despite the dose-dependent association shown in our 
Table 3 Haloperidol and clonidine dosage on day X and delirium resolution on the following day
Markov regression model (Model 2). Mortality or discharge on day X + 1 was included as a competing event. Model fit: χ2(54) = 13,529.869, p < 0.001
CI confidence interval, Mg milligram, OR Odds ratio
a Adjusted for age, APACHE IV score, admission type (acute surgery, elective surgery, medical reason), patients’ mental status on day X, modified SOFA score, 
metabolic acidosis, use of ventilation, and administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids
Mental status 
on day X
Exposure on day X Mental status on day X + 1 Adjusted OR (95% CI)a p value
Delirious No haloperidol or clonidine Delirious or unarousable Reference
Delirious Haloperidol dose (per 1 mg in 24 h) Awake without delirium 0.84 (0.81–0.88) < 0.001
Delirious Clonidine dose (per 0.1 mg in 24 h) Awake without delirium 0.98 (0.97–1) 0.023
cohort, the dosages might have been too low to deliver a 
positive effect on delirium resolution.
The efficacy of clonidine, alone or in combination with 
haloperidol, as ICU delirium treatment has been studied 
less extensively, possibly because intravenous clonidine is 
not available in the United States. A small placebo-con-
trolled prevention trial in patients who underwent surgi-
cal correction of acute type-A aortic dissection showed 
no beneficial effect of intravenous clonidine on delirium 
incidence, but did report lower delirium severity [18]. 
Our results may challenge clonidine as treatment in all 
patients with delirium. However, confirmation in a rand-
omized trial or another cohort study is warranted.
While we had expected that treatment with halop-
eridol and/or clonidine would increase the likelihood 
of resolving delirium, our results do not support this. 
An explanation may be that haloperidol and clonidine 
induce hypoactive symptoms, and thereby interfere with 
delirium assessment. However, haloperidol and clonidine 
dosages in our cohort were relatively low. Subsequently, 
the probability of false positive delirium assessments 
due to sedative effects of these drugs is likely to be low. 
In addition, our primary outcome comparator involved 
a combination of delirium and unarousable state and 
not exclusively delirium, and the validated delirium algo-
rithm that was used to classify delirium was based on a 
comprehensive assessment of several other symptoms of 
delirium [22].
A few other limitations should be considered. First, this 
was a single-center observational study in patients who 
were mostly mechanically ventilated, which may limit 
generalizability. Second, classifying a patients’ mental 
status as being either awake without delirium, delirium 
or unarousable on a daily basis may be a simplification, 
Table 4 Secondary outcomes in delirious patients from administration of haloperidol, clonidine or both during ICU stay
Regression models adjusted for age, APACHE IV score, admission type, highest modified SOFA score during ICU stay, presence of metabolic acidosis during ICU stay, 
ventilation during ICU stay, administration of any antipsychotic other than haloperidol, benzodiazepines, propofol and opioids during ICU stay, and delirium duration
CI confidence interval, ICU Intensive Care Unit, LOS length of stay, OR Odds ratio
a Linear regression after log transformation due to skewed distribution of residuals
b Model is a good fit to the data. Delirium duration: F(12,1002) = 37.532, p < 0.0001, R2 = 0.310; delirium days: F(13,1071) = 124.531, p < 0.001, R2 = 0.602; ventilation 
days: F(12,1045 = 58.617, p < .001, R2 = 0.402; ICU LOS: F(13,1071) = 71.937, p < 0.001, R2 = 0.466; Hospital LOS: F(13,1071) = 20.792, p < 0.001, R2 = 0.202; ICU mortality: 
Hosmer and Lemeshow test p = 0.545
c Logistic regression analysis
Secondary outcome Exposure during ICU stay Adjusted exp(B) 95% CI p value
Delirium  durationa,b No haloperidol or clonidine Reference
Clonidine only 1.08 1.02–1.16 0.015
Haloperidol only 1.27 1.19–1.35 < 0.001
Both haloperidol and clonidine 1.44 1.36–1.52 < 0.001
Delirium  daysa,b No haloperidol or clonidine Reference
Clonidine only 1.05 1–1.1 0.040
Haloperidol only 1.23 1.17–1.28 < 0.001
Both haloperidol and clonidine 1.3 1.24–1.35 < 0.001
Ventilation  daysa,b No haloperidol or clonidine Reference
Clonidine only 1.06 0.99–1.13 0.108
Haloperidol only 1 0.94–1.07 0.920
Both haloperidol and clonidine 1.11 1.04–1.17 0.001
ICU  LOSa,b No haloperidol or clonidine Reference
Clonidine only 1.06 1–1.13 0.043
Haloperidol only 1.07 1.01–1.13 0.017
Both haloperidol and clonidine 1.16 1.1–1.22 < 0.001
Hospital  LOSa,b No haloperidol or clonidine Reference
Clonidine only 1.02 0.98–1.09 0.519
Haloperidol only 1.07 1–1.13 0.042
Both haloperidol and clonidine 1.11 1.05–1.18 < 0.001
ICU  mortalityb,c No haloperidol or clonidine Reference
Clonidine only 0.47 0.22–1.03 0.059
Haloperidol only 1.16 0.6–2.21 0.665
Both haloperidol and clonidine 0.65 0.35–1.2 0.169
as mental status may not be categorizable and delirium 
may fluctuate over the course of the day. Similarly, some 
delirious patients may have experienced rapidly revers-
ible, sedation-related delirium, which seem to have a 
prognosis similar to that seen in non-delirious patients 
[37, 38]. Third, we did not examine whether haloperidol 
and clonidine were associated with reduction of psy-
chotic features and agitation. Hence, we are not able to 
make any recommendations regarding treatment of such 
features. A last important methodological concern is 
that daily transitions of mental states were assumed to 
be independent of the patient history beyond the prior 
day. While the covariables were derived from a system-
atic review [31], it is possible that unmeasured confound-
ing influenced the results. Additionally, despite using 
propensity scoring to match groups, more patients with 
severe delirium, and thus a low risk of delirium resolu-
tion, may have received haloperidol or clonidine than 
patients who had lower delirium severity, which can be 
regarded as confounding by indication. The sensitivity 
analysis with respect to delirium subtypes may have dealt 
with any possible confounding by delirium motor sub-
types or delirium severity. It would be important to study 
the treatment effects of haloperidol and clonidine in a 
future randomized clinical trial.
A key strength is that this study is the first to investi-
gate haloperidol and clonidine as delirium treatment, 
both separately as well as in combination, in the same 
study population. We made use of a validated delirium-
recognition algorithm that advocated frequent CAM-
ICU assessment and incorporated additional criteria to 
define delirium [22]. Another strength is the large sam-
ple size, allowing us to adjust for numerous confounders. 
Additionally, we could investigate temporal relationships 
between administration of medication and transitions of 
mental states, which allowed us to take account of the 
factors that varied over time during ICU admission.
Conclusion
In conclusion, this large cohort study suggests that 
administration of haloperidol, clonidine, or both, in 
delirious ICU patients may be associated with reduced 
probabilities of short-term delirium resolution and 
worse short-term clinical outcomes, such as longer delir-
ium episodes and longer ICU stay. However, although 
adjusted for known confounders, these results should 
be regarded as hypothesis generating and future studies 
are needed to inform clinical practice. We suggest that in 
such studies symptomatic treatment of psychotic features 
or agitation should be differentiated from delirium diag-
nosis as a syndrome.
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